-
-
-
Fosun International Achieves AA- in HSI ESG Rating for Third Consecutive Year, Marks Sixth Year as Constituent of Hang Seng Corporate Sustainability Benchmark Index
2025-09-14
On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International” or the “Company”) was informed that in the 2025 Sustainability Ratings of listed companies released by Hang Seng Indexes Company, Fosun International received an AA- rating for the third consecutive year.
-
-
-
-
Fosun International Holds Signing Ceremony for USD910 Million Equivalent Syndicated Loan, Underscoring Global Market Confidence in its Future Development
2025-09-10
On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International”, “Fosun”, or the “Company”) held the signing ceremony for its 2025 three-year sustainability-linked syndicated loan in Hong Kong.
-
-
-
-
Fosun International Recognized among Fortune’s 2025 “Most Admired Chinese Companies” List
2025-09-10
On 9 September, Fortune China magazine released its 2025 list of “Most Admired Chinese Companies”, in which Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was included in the Industry Star List.
-
-
-
-
U.S. FDA Clearance of IND for Pembrolizumab Biosimilar HLX17
2025-09-09
Shanghai, China, September 8, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced the investigational new drug (IND) application for its HLX17, a proposed pembrolizumab biosimilar independently developed by the company, was approved by the U.S. Food and Drug Administration (FDA) as an adjuvant therapy for certain resected solid tumors,
-
-
-
-
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-09-02
SHANGHAI, China & JERSEY CITY, NJ – September 2, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.
-
-
-
-
Lanvin Group Reports H1 2025 Revenue of €133 Million Operational Discipline and Early Recovery Momentum Set Foundation for Growth in H2
2025-08-30
August 29, 2025 -- Lanvin Group (NYSE: LANV, the "Group"), a global luxury fashion group with Lanvin, Wolford, Sergio Rossi, St. John and Caruso in its portfolio of brands, today announced its unaudited results for the first half of 2025. Despite ongoing industry-wide pressures, the Group delivered performance underpinned by strong cost discipline, operational efficiency, and visible signs of recovery in the second quarter.
-
-
-
-
Fosun Pharma Gains Exclusive Rights for Accro's Novel Small-Molecule Drug Candidate AC-201 in Greater China
2025-08-30
Shanghai, China, August 29, 2025 – Fosun Pharma (600196.SH; 02196.HK) and Accro Bioscience (Accro) today announced that Accro will grant exclusive rights to develop, manufacture, and commercialize its independently developed, highly selective TYK2/JAK1 inhibitor to Fosun Pharma in Greater China (including Chinese Mainland, Hong Kong SAR, and Macau SAR). Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR).
-
-
-
-
Fosun International Hosts 2025 Interim Results Presentation, Reaffirms Confidence in Future Development Driven by Innovation and Globalization
2025-08-29
On the morning of 29 August, Fosun International held an interim results presentation in Shanghai, with attendees including Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu, Co-CEO of Fosun International, Xu Xiaoliang, Co-CEO of Fosun International, Gong Ping, CFO of Fosun International, along with numerous institutional investors and analysts.
-
-
-
-
Fosun Pharma’s Immunomodulatory Small Molecule Inhibitor Achieves Overseas Licensing
2025-08-28
(August 27, 2025, Shanghai, China)— Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has entered into a License Agreement with Sitala, a UK-based biotech company focused on developing innovative drugs for inflammation and autoimmune diseases. Under the agreement, Fosun Pharma Industrial will grant Sitala exclusive rights to develop, manufacture, and commercialize the small molecule inhibitor FXS6837 and products containing this active ingredient globally (except Chinese Mainland, Hong Kong SAR and Macau SAR). The licensed field includes the diagnosis and treatment of human and animal diseases. Fosun Pharma will retain the rights to develop, manufacture, and commercialize FXS6837 in Chinese Mainland, Hong Kong SAR and Macau SAR.
-